STAT Inhibitors for Cancer Therapy

Authors

Muhammad Furqan, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA. delong_liu@nymc.edu.
Akintunde Akinleye
Nikhil Mukhi
Varun Mittal
Yamei Chen
Delong Liu

Author Type(s)

Faculty

DOI

10.1186/1756-8722-6-90

Journal Title

Journal of Hematology & Oncology

First Page

90

Document Type

Article

Publication Date

12-5-2013

Abstract

Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides. This review summarized advances in preclinical and clinical development of these compounds.

Recommended Citation

Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., & Liu, D. (2013). STAT Inhibitors for Cancer Therapy. Journal of Hematology & Oncology, 6, 90. https://doi.org/10.1186/1756-8722-6-90